[1] 吴永佩，蔡映云.临床药物治疗学总论[M].北京：人民卫生出版社，2018

[2] A.David Rodrigues.Drug-Drug Interations.Second Edition[M]. Informa healthcare,2008

[3] 卫生部合理用药专家委员会.中国医师药师临床用药指南[DB].MCDEX v3,2021

[4] De Jong J, Haddish-Berhane N, Hellemans P, et al. The pH-altering agent omeprazole affects rate but not the extent of ibrutinib exposure[J]. Cancer Chemother Pharmacol,2018,82(2):299-308.

[5] Ying C Ou, Zhiyu Tang, William Novotny,et al.Evaluation of drug interaction potential of zanubrutinib with cocktail probes representative of CYP3A4, CYP2C9, CYP2C19, P-gp and BCRP[J].Br J Clin Pharmacol. 2021 Jul;87(7):2926-2936.

[6] Xavier J.H. Pepin, Andrea J. Moir, James C. Mann,et al.Bridging in vitro dissolution and in vivo exposure for acalabrutinib. Part II. A mechanistic PBPK model for IR formulation comparison, proton pump inhibitor drug interactions, and administration with acidic juices[J].Eur J Pharm Biopharm. 2019 Sep;142:435-448.

[7] Ahmed Hamed Salem, Beibei Hu , Kevin J Freise，et al.Evaluation of the Pharmacokinetic Interaction between Venetoclax, a Selective BCL-2 Inhibitor, and Warfarin in Healthy Volunteers[J].Clin Drug Investig. 2017 Mar;37(3):303-309.

[8] Jan de Jong, Anna Mitselos  Wojciech Jurczak，et al.Ibrutinib does not have clinically relevant interactions with oral contraceptives or substrates of CYP3A and CYP2B6[J].Pharmacol Res Perspect. 2020 Oct;8(5):e00649.

[9] Ying C Ou, Zhiyu Tang, William Novotny,et al.Evaluation of drug interaction potential of zanubrutinib with cocktail probes representative of CYP3A4, CYP2C9, CYP2C19, P-gp and BCRP[J].Br J Clin Pharmacol. 2021 Jul;87(7):2926-2936.

[10] Feng Jin,Michelle Robeson, Huafeng Zhou,et al.Clinical drug interaction profile of idelalisib in healthy subjects[J].J Clin Pharmacol. 2015 Aug;55(8):909-19.

[11] Manoj S Chiney, Rajeev M Menon, Orlando F Bueno,et al.Clinical evaluation of P-glycoprotein inhibition by venetoclax: a drug interaction study with digoxin[J].Xenobiotica. 2018,48(9):904-910.

[12] Feng Jin , Michelle Robeson, Huafeng Zhou,et al.Clinical drug interaction profile of idelalisib in healthy subjects[J].J Clin Pharmacol. 2015 Aug;55(8):909-919.

[13] Ruchlemer R, Ben-Ami R, Bar-Meir M, et al. Ibrutinib-associated invasive fungal diseases in patients with chronic lymphocytic leukemia and non Hodgkin lymphoma: an observational study[J]. Mycoses,2019,62:1140-1147.

[14] Messina JA, Maziarz EK, Spec A, et al. Disseminated cryptococcosis with brain involvement in patients with chronic lymphoid malignancies on ibrutinib[J]. Open Forum Infect Dis,2017, 4:ofw261.

[15] Chamilos G, Lionakis MS, Kontoyiannis DP. Call for action: invasive fungal infections associated with ibrutinib and other small molecule kinase inhibitors targeting immune signaling pathways[J]. Clin Infect Dis,2018, 66:140-148.

[16] Jan de Jong, Juthamas Sukbuntherng, Donna Skee,et al.The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia[J].Cancer Chemother. Pharmacol,2015,75: 907-916.

[17] Fujita K.Food-drug interactions via human cytochrome P450 3A (CYP3A)[J].Drug Metabol Drug Interact. 2004;20(4):195-217.

[18] 章冉冉，阳国平，荆宁宁等.食物对细胞色素P450药物代谢酶的影响.中国临床药理学与治疗学.2014,19（2）：200-206

[19] Meng Chen, Shu-Yi Zhou, Erlinda Fabriaga,et al.Food-drug interactions precipitated by fruit juices other than grapefruit juice: An update review.J Food Drug Anal. 2018 Apr;26(2S):S61-S71.

[20] Sparreboom A, Cox MC, Acharya MR, Figg WD. Herbal remedies in the United States: potential adverse interactions with anticancer agents. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004; 22(12):2489–2503.

[21] Fujita K.Food-drug interactions via human cytochrome P450 3A (CYP3A).Drug Metabol Drug Interact. 2004;20(4):195-217.

[22] Ibrutinib/Zanubrutinib/Acalabrutinib/Orelabrutinib/Venetoclax/Idelalisib/Duvelisib/Copanlisib©2021 UpToDate,Inc.

[23] https://www.drugs.com/drug_interactions.html